CONCLUSION: ADAM-101 as an adjunct to pharmacotherapy showed preliminary benefits in clinician- and parent-rated symptom severity and auditory attention, without significant safety concerns. Larger confirmatory trials are warranted.
CONCLUSION: ADAM-101 as an adjunct to pharmacotherapy showed preliminary benefits in clinician- and parent-rated symptom severity and auditory attention, without significant safety concerns. Larger confirmatory trials are warranted.